Northern Biologics announces global acquisition of clinical-stage antibody MSC-1 by AstraZeneca

An AstraZeneca subsidiary agreed in November 2020 to acquire MSC-1, the lead asset of Northern Biologics. MSC-1 is an anti-LIF antibody that had completed Phase 1a clinical studies in solid tumours. Deal terms were not disclosed. Metrix Partners has worked with Mosaic Biomedicals, an affiliate of Northern Biologics, since its early stage.

AstraZeneca acquisition of MSC-1 from Northern Biologics

About MSC-1

MSC-1 is a humanised antibody against leukaemia inhibitory factor (LIF), a cytokine that plays several roles in cancer. Blocking LIF opens two possible effects: reversing immune suppression in the tumour and blocking the growth of cancer-initiating cells. The antibody was originally developed by Mosaic Biomedicals in Barcelona and brought into Northern Biologics through a merger in 2016.

The first patients were dosed in 2018 at Memorial Sloan Kettering Cancer Center. Results of the Phase 1 dose-escalation study were presented at the AACR annual meeting in 2020 and showed the antibody was safe and well tolerated in patients with advanced solid tumours.

The AstraZeneca deal

MSC-1 was Northern Biologics’ only remaining asset after Boehringer Ingelheim acquired its preclinical pipeline in May 2020. Philip Vickers, President and CEO of Northern Biologics, said the transaction with AstraZeneca could accelerate and expand the development of MSC-1. The deal is referred to in AstraZeneca’s 2020 annual report.

Asset deals in biotech

Large pharmaceutical companies often buy individual drug candidates rather than whole companies. For the seller, an asset sale can deliver value to investors while leaving the company free to wind down or pursue other programmes. For the buyer, it brings a specific asset into its pipeline without taking on unrelated activities, staff or liabilities.

Five lessons from the MSC-1 sale

  1. Clinical data creates value. Completing Phase 1a gave buyers safety data and reduced risk.
  2. Several buyers can split a portfolio. Northern Biologics sold its preclinical programmes and its clinical asset to two different groups.
  3. IP history must be clean. MSC-1 moved from Mosaic to Northern Biologics. Clear chains of ownership make later deals possible.
  4. Deal terms are often contingent. Asset deals usually include upfront payments, milestones and royalties. Their value depends on future development.
  5. Investor syndicates shape exits. Specialist investors such as Versant Ventures know how to package assets for big pharma buyers.

What biotech founders should prepare for partnering or a sale

  • A data room with preclinical and clinical data, organised by programme.
  • A clear IP chain of title for each asset.
  • Financial accounts reconciled to the statutory filings, with programme costs tracked separately.
  • A summary of all licences, options and partner rights.
  • A view on deal structures and their tax treatment.

Metrix Partners in life sciences

Metrix has supported life sciences clients through financing and exits. The Northern Biologics transactions with Boehringer Ingelheim and AstraZeneca are among the notable deals involving companies Metrix has worked with, alongside Aelix Therapeutics and Ona Therapeutics.